Navigation Links
First Multiple Dose Clinical Trial of TorreyPines Therapeutics' Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated
Date:2/11/2009

Findings Support Development for Chronic Pain Indications

LA JOLLA, Calif., Feb. 11 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced that oral administration of NGX426, an AMPA/kainate-type glutamate receptor antagonist, was safe and well-tolerated in healthy male and female subjects when dosed once daily for five consecutive days.

"The successful completion of this Phase I trial demonstrating the safety and tolerability of NGX426 when dosed over multiple days provides support for pursuing a Phase II program in chronic indications," said Ev Graham, Chief Executive Officer of TorreyPines. "Combined with the positive results from our recently completed Phase I study of NGX426 in a capsaicin induced pain model, we are very encouraged about the potential for NGX426 to treat both acute and chronic pain conditions."

The Phase I double-blind, placebo-controlled trial enrolled 20 healthy male and female subjects in sequential, dose-escalating cohorts. Subjects received once-daily oral doses of either 90 mg or 150 mg of NGX426 or placebo for five consecutive days, approximating exposure under steady-state pharmacokinetic conditions. Overall, NGX426 was well-tolerated. There were no dose-limiting adverse events or discontinuations from the study and reported adverse events were generally mild and transient.

NGX426, an ester prodrug, is an oral form of tezampanel, TorreyPines most advanced product candidate. Pharmacokinetic analyses from two Phase I studies confirmed that when given to humans, NGX426 is rapidly converted to tezampanel, the active moiety. To date, six Phase II, double-blind, placebo-controlled trials have demonstrated that tezampanel, administered either subcutaneously or intravenously, was more effective than placebo in relieving pain across migraine, nocic
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Max Muscle Introduces First-Ever Probiotics Protein Bar
2. Pharmasset Reports Fiscal First Quarter 2009 Financial Results
3. Hoya Announces Third Quarter and the First Nine Months Financial Results for FY2008
4. Historic Seed Delivery Made in Illinois for First New Soybean Varieties With the Greater Yield Potential of Roundup Ready 2 Yield(TM)
5. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study
6. World's First Website for Patients to Share Diagnostic-Quality Medical Images
7. Victhom Human Bionics Receives CE Mark for the Neurostep(TM) System, the Worlds First Fully Implantable Closed-Loop Neuromodulation Therapy for Treatment of Foot Drop
8. BioComp Pharma Launches First Generic Drug for Tindamax(R)
9. deCODE Discovers First Genetic Variant Conferring Increased Risk of Essential Tremor
10. Complete Genomics to Release Its DNA Sequencing Data for the First Time at Advances in Genome Biology and Technology Annual Meeting
11. AMDL First to Implement US & China-Based, GAAP-Certified Accounting Technology to Capitalize on Lucrative China Healthcare Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... , March 4, 2015  BioClinica®, Inc., ... technology provider, today announced that clinical trial ... convened at its annual European User Conference ... to discuss the use of its eClinical ... eClinical technologies include: the Microsoft Office-Smart OnPoint ...
(Date:3/4/2015)... 2015   ... und Therapie, Strahlendosismanagement und IT-Lösungen für die gesamte ... Philips (NYSE: PHG, AEX: PHIA) gab heute ... (ECR) bekannt, der vom 4. bis 8. März in ... Ständen Nr. 102 and 110 wird das ...
(Date:3/3/2015)... 2015 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") ... for odour control projects in North America , ... . "Bidding activity in 2015 continues to be ... a high volume year for bidding in 2014, we are pleased ... recent orders reflect the organization,s renewed focus on select market segments ...
(Date:3/3/2015)... Ark. (PRWEB) March 03, 2015 ... Systems Inc. to their international sales network. The ... gas dissolution technology to Canada’s Atlantic Provinces, exclusively ... has served as one of Canada’s premiere manufacturing ... in both the municipal water and wastewater markets. ...
Breaking Biology Technology:BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 2BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 3Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 2Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 3Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 4Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 5Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 6BlueInGreen® Continues Canadian Expansion, Partners with Resource Systems Inc. 2
... , AUSTIN, Texas , Feb. 15 ... San Antonio , is presenting at the 5th Annual Stem Cell ... Dr. Johnson will be presenting his most recent data proving the efficacy ... of care technology utilizes the patient,s own cells derived from bone marrow ...
... to the term "power suit," University of California, Berkeley, ... be woven into clothing and textiles. These ... convert into electricity the energy created through mechanical stress, ... lead to wearable ,smart clothes, that can power hand-held ...
... , MINNEAPOLIS , Feb. 12 CoAxia™, ... completion of enrollment in its SENTIS randomized, controlled, pivotal trial ... for ischemic stroke.  The Company plans to complete data collection ... warranted, submit a PMA to the US FDA. , Ischemic ...
Cached Biology Technology:SpineSmith to Present at the 5th Annual Stem Cell Summit 2SpineSmith to Present at the 5th Annual Stem Cell Summit 3New fiber nanogenerators could lead to electric clothing 2CoAxia Announces Completion of Enrollment in Ischemic Stroke Trial 2CoAxia Announces Completion of Enrollment in Ischemic Stroke Trial 3
(Date:2/13/2015)... 13, 2015 ACT Genomics Co., Ltd., ... to transform cancer genomic information into precision diagnosis ... has raised US$ 8 million in the its first ... Taipei, Taiwan , ACT Genomics has ... the aim to implement next generation sequencing (NGS) ...
(Date:2/12/2015)... 12, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... 62/113114 for DISTRIBUTED METHOD AND SYSTEM TO ... patent further establishes NXT-ID,s position in the emerging "Internet ... the ability for multiple devices to collaborate with one ...
(Date:2/10/2015)... 10, 2015  Alere Inc. (NYSE: ALR), a ... results for the quarter ended December 31, 2014. ... President of Alere said, "We made substantial progress ... the global leader in rapid diagnostics and delivering ... Health divestiture in early January enabled us to ...
Breaking Biology News(10 mins):ACT Genomics Raises $8 Million in its First Private Funding Round 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33
... after all when it comes to Alzheimer’s disease. , ... Investigation, a team of scientists from the University of Rochester ... villain when it comes to parsing out damage after a ... in Alzheimer’s disease, protecting the brain and helping get rid ...
... greenhouse gases and increase production at the same time has ... Primary Industries' (DPI) Wollongbar Agricultural Institute. , Trials of agrichar ... soils and the environment - have doubled and, in one ... 10 tonnes per hectare. , Agrichar is a ...
... Why do so many people continue to suffer from life-altering, ... The definitive answer -- and an effective treatment -- has ... morphine derivatives, haven’t worked very well. , A ... pain appears to be an old memory trace that essentially ...
Cached Biology News:Brain inflammation may be friend, not foe, for Alzheimer's patients 2Brain inflammation may be friend, not foe, for Alzheimer's patients 3Brain inflammation may be friend, not foe, for Alzheimer's patients 4Soils offer new hope as carbon sink 2Soils offer new hope as carbon sink 3Old memory traces in brain may trigger chronic pain 2Old memory traces in brain may trigger chronic pain 3